Impact BioMedical
18 hedge funds and large institutions have $358K invested in Impact BioMedical in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
112% more capital inflows, than outflows
Capital inflows: $80.4K | Capital outflows: $38K
20% more funds holding
Funds holding: 15 → 18 (+3)
0.52% more ownership
Funds ownership: 3.9% → 4.42% (+0.52%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44.4K |
| 2 |
Two Sigma Securities
New York
|
+$17.9K |
| 3 |
Mason & Associates (California)
Los Angeles,
California
|
+$6.3K |
| 4 |
Morgan Stanley
New York
|
+$5.84K |
| 5 |
Two Sigma Investments
New York
|
+$5.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$12.4K |
| 2 |
StoneX Group
New York
|
-$6.99K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.22K |
| 4 |
HRT Financial
New York
|
-$6K |
| 5 |
Citigroup
New York
|
-$3.4K |
IBO Hedge Fund Activity: Q3 2025 in Review
18 of the 7,658 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q3 2025, worth a combined $358K — up 18% from $305K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IBO positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $44.4K. The largest seller was UBS Group, cutting an estimated $12.4K.
- 18 institutional investors held Impact BioMedical (IBO) as of Q3 2025, up from 15 in Q2 2025.
- Funds reported $358K of Impact BioMedical stock for Q3 2025, up 18% quarter-over-quarter.
- 5 funds opened new Impact BioMedical positions in Q3 2025 and 2 closed out, a net change of +3 holders.
- The largest Impact BioMedical buyer in Q3 2025 was Vanguard Group, an estimated $44.4K added.
- The largest Impact BioMedical seller in Q3 2025 was UBS Group, an estimated $12.4K sold.
Based on aggregated 13F filings for Q3 2025.